Non-small-cell lung cancers: a heterogeneous set of diseases
Zhao Chen, Christine F. Brainson, Peter S. Hammerman et al. · Nature reviews. Cancer · 2014
Cited by 1,942 works. doi:10.1038/nrc3775
Authors
References
- Global cancer statistics
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Mutations of the BRAF gene in human cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Cancer statistics, 2013
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer